JPWO2020150639A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020150639A5 JPWO2020150639A5 JP2021541578A JP2021541578A JPWO2020150639A5 JP WO2020150639 A5 JPWO2020150639 A5 JP WO2020150639A5 JP 2021541578 A JP2021541578 A JP 2021541578A JP 2021541578 A JP2021541578 A JP 2021541578A JP WO2020150639 A5 JPWO2020150639 A5 JP WO2020150639A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- diazo
- pharmaceutically acceptable
- acetamido
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 201000011510 cancer Diseases 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 9
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 3
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- YCWQAMGASJSUIP-YFKPBYRVSA-N 6-diazo-5-oxo-L-norleucine Chemical compound OC(=O)[C@@H](N)CCC(=O)C=[N+]=[N-] YCWQAMGASJSUIP-YFKPBYRVSA-N 0.000 claims 2
- 229960005538 6-diazo-5-oxo-L-norleucine Drugs 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- LQNMCWOJACNQQM-PMACEKPBSA-N CC(C)OC(=O)[C@H](CCC(=O)C=[N+]=[N-])NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(C)=O Chemical compound CC(C)OC(=O)[C@H](CCC(=O)C=[N+]=[N-])NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(C)=O LQNMCWOJACNQQM-PMACEKPBSA-N 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- BFGQSHBGAAGGRX-IRXDYDNUSA-N (2S)-2-[[(2S)-2-acetamido-3-(1H-indol-3-yl)propanoyl]amino]-6-diazo-5-oxohexanoic acid Chemical compound C(C)(=O)N[C@H](C(=O)N[C@H](C(=O)O)CCC(C=[N+]=[N-])=O)CC1=CNC2=CC=CC=C12 BFGQSHBGAAGGRX-IRXDYDNUSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- 229940126214 compound 3 Drugs 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229950010773 pidilizumab Drugs 0.000 claims 1
- 229950007213 spartalizumab Drugs 0.000 claims 1
- 229950007217 tremelimumab Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962794231P | 2019-01-18 | 2019-01-18 | |
| US62/794,231 | 2019-01-18 | ||
| PCT/US2020/014149 WO2020150639A1 (en) | 2019-01-18 | 2020-01-17 | Combinaton therapy with a don prodrug and an immune checkpoint inhibitor |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022518232A JP2022518232A (ja) | 2022-03-14 |
| JP2022518232A5 JP2022518232A5 (https=) | 2023-01-27 |
| JPWO2020150639A5 true JPWO2020150639A5 (https=) | 2023-01-27 |
| JP7574198B2 JP7574198B2 (ja) | 2024-10-28 |
Family
ID=71614516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021541578A Active JP7574198B2 (ja) | 2019-01-18 | 2020-01-17 | Ｄｏｎプロドラッグおよび免疫チェックポイント阻害剤による組み合わせ治療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220117938A1 (https=) |
| EP (1) | EP3911310A4 (https=) |
| JP (1) | JP7574198B2 (https=) |
| KR (1) | KR20210117303A (https=) |
| CN (1) | CN113438947A (https=) |
| AU (1) | AU2020208637A1 (https=) |
| BR (1) | BR112021014112A2 (https=) |
| CA (1) | CA3126822A1 (https=) |
| EA (1) | EA202191992A1 (https=) |
| IL (1) | IL284907A (https=) |
| MX (1) | MX2021008546A (https=) |
| SG (1) | SG11202107317WA (https=) |
| WO (1) | WO2020150639A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3153424A1 (en) * | 2019-10-03 | 2021-04-08 | Dracen Pharmaceuticals, Inc. | Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereof |
| WO2022022612A1 (en) * | 2020-07-29 | 2022-02-03 | Jacobio Pharmaceuticals Co., Ltd. | Novel glutamine analogs |
| JP7846686B2 (ja) * | 2020-10-02 | 2026-04-15 | ドラセン ファーマシューティカルズ インコーポレイテッド | 皮下投与のための（ｓ）－イソプロピル２－（（ｓ）－２－アセトアミド－３－（１ｈ－インドール－３－イル）プロパンアミド）－６－ジアゾ－５－オキソヘキサノエートを含む凍結乾燥組成物およびその使用 |
| EP4229029B1 (en) * | 2020-10-15 | 2026-02-25 | Jacobio Pharmaceuticals Co., Ltd. | Novel glutamine analogs |
| CN114621120B (zh) * | 2020-12-10 | 2023-11-03 | 深圳先进技术研究院 | 一种don前药分子、前药激活化合物和前药激活体系 |
| US20240246902A1 (en) * | 2021-04-29 | 2024-07-25 | The Johns Hopkins University | Prodrugs of 6-diazo-5-oxo-l-norleucine |
| WO2022261117A1 (en) * | 2021-06-07 | 2022-12-15 | Dracen Pharmaceuticals, Inc. | Combination therapy with a don prodrug and a tigit inhibitor |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US6605712B1 (en) | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| WO2013043569A1 (en) | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| NZ718821A (en) | 2013-09-11 | 2022-07-01 | Medimmune Ltd | Anti-b7-h1 antibodies for treating tumors |
| EP3113798B1 (en) | 2014-03-07 | 2019-06-05 | University Health Network | Methods and compositions for modifying the immune response |
| US20160113925A1 (en) * | 2014-10-22 | 2016-04-28 | Emory University | Methods of treating cancer with a combination of glucose modulators and bcl-2 inhibitors |
| CA2994165A1 (en) | 2015-07-31 | 2017-02-09 | The Johns Hopkins University | Methods for cancer and immunotherapy using glutamine analogues, including don |
| EP3328374A4 (en) | 2015-07-31 | 2019-03-13 | The Johns Hopkins University | GLUTAMINANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITES |
| AU2016302940B2 (en) | 2015-07-31 | 2021-02-04 | The Johns Hopkins University | Prodrugs of glutamine analogs |
| US20180244783A1 (en) * | 2015-08-31 | 2018-08-30 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| CN110869765A (zh) * | 2017-04-20 | 2020-03-06 | Adc治疗有限公司 | 组合疗法 |
| CN111566083A (zh) * | 2017-10-06 | 2020-08-21 | 约翰·霍普金斯大学 | 新的谷氨酰胺拮抗剂及其用途 |
-
2020
- 2020-01-17 SG SG11202107317WA patent/SG11202107317WA/en unknown
- 2020-01-17 EA EA202191992A patent/EA202191992A1/ru unknown
- 2020-01-17 CN CN202080013742.1A patent/CN113438947A/zh active Pending
- 2020-01-17 KR KR1020217026015A patent/KR20210117303A/ko not_active Ceased
- 2020-01-17 BR BR112021014112-0A patent/BR112021014112A2/pt not_active IP Right Cessation
- 2020-01-17 AU AU2020208637A patent/AU2020208637A1/en not_active Abandoned
- 2020-01-17 CA CA3126822A patent/CA3126822A1/en active Pending
- 2020-01-17 US US17/423,819 patent/US20220117938A1/en not_active Abandoned
- 2020-01-17 EP EP20741361.8A patent/EP3911310A4/en not_active Withdrawn
- 2020-01-17 WO PCT/US2020/014149 patent/WO2020150639A1/en not_active Ceased
- 2020-01-17 MX MX2021008546A patent/MX2021008546A/es unknown
- 2020-01-17 JP JP2021541578A patent/JP7574198B2/ja active Active
-
2021
- 2021-07-18 IL IL284907A patent/IL284907A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6961897B2 (ja) | 癌治療のためのｔ細胞活性化及び／又はチェックポイント阻害剤を組み合わせたペプチド及びペプチド模倣物 | |
| JP2018501197A5 (https=) | ||
| JP2020514310A5 (https=) | ||
| TW201918263A (zh) | 抗體－藥物結合物之改良製造方法 | |
| JP2020519295A5 (https=) | ||
| JP2020510662A5 (https=) | ||
| JP2016539096A5 (https=) | ||
| JP2020536109A5 (https=) | ||
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| JP2010535713A5 (https=) | ||
| JP2017113019A5 (https=) | ||
| JP2017510661A5 (https=) | ||
| RU2018105846A (ru) | Комбинация антагониста pd-1 с ингибитором egfr | |
| JP2019506403A5 (https=) | ||
| JP2019501145A5 (https=) | ||
| RU2007135167A (ru) | Комбинированная терапия с использованием анти-ctla4-антитела и индолинона для лечения рака | |
| JP2021525765A5 (https=) | ||
| JP2016128399A5 (https=) | ||
| JP2021510697A5 (https=) | ||
| JP2021531255A5 (https=) | ||
| JPWO2020150639A5 (https=) | ||
| JP2021521274A5 (https=) | ||
| JP2008526859A (ja) | トリペプチドおよびテトラペプチドチオエーテル | |
| JPWO2021123996A5 (https=) | ||
| JPWO2019232433A5 (https=) |